Stay updated on India’s healthcare and pharma landscape. In this episode, we cover the flood of low-cost semaglutide generics after patent expiry, sharp price drops improving access for diabetes patients, rising concerns over misuse as a weight-loss drug, and increased regulatory scrutiny on sales and advertising.